AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial - Reuters

1diawanita.blogspot.com

• Companies

• AstraZeneca PLC

Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat unresectable, Stage 3 non-small cell lung cancer.

Imfinzi administered sequentially after platinum-based CRT is already an established standard of care for the treatment of that type of lung cancer.

But the so-called "PACIFIC-2 Phase 3" trial for Imfinzi concurrently administered with platinum-based chemoradiotherapy (CRT) aimed to address patients who progress or discontinue treatment during CRT, the London-listed company said.

The trial did not achieve statistical significance for progression-free survival versus CRT alone, it said, adding that its initial analysis of the safety and tolerability profile showed there was an increased rate of infection during the concurrent treatment period in the experimental arm.

Reporting by Yadarisa Shabong in Bengaluru; Editing by Rashmi Aich

Our Standards: The Thomson Reuters Trust Principles.

Acquire Licensing Rights, opens new tab

Adblock test (Why?)

"stage" - Google News
November 15, 2023 at 05:01AM
https://ift.tt/ef9NSAb

AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial - Reuters
"stage" - Google News
https://ift.tt/dr1yjlQ
https://ift.tt/WbvPSja

Bagikan Berita Ini